Results of a clinical study of the efficacy and safety of Panavir® in the therapy of post-primary herpetic keratitis
Year: 2022, volume 18 Issue: №4 Pages: 657-661
Heading: Тhematic supplement Article type: Original article
Authors: Veselova Е.М., Kamenskikh T.G., Kiselev A.V., Shadenkov D.A., Gileva E.V., Gubareva N.N.
Organization: Saratov State Medical University, National Research Company LLC, Moscow, Russia, N. N. Semenov Federal Research Center for Chemical Physics Russian Academy of Sciences, Moscow, Russia
Heading: Тhematic supplement Article type: Original article
Authors: Veselova Е.М., Kamenskikh T.G., Kiselev A.V., Shadenkov D.A., Gileva E.V., Gubareva N.N.
Organization: Saratov State Medical University, National Research Company LLC, Moscow, Russia, N. N. Semenov Federal Research Center for Chemical Physics Russian Academy of Sciences, Moscow, Russia
Summary:
Abstract. Objective: to analyze the efficacy, safety and tolerability of Panavir® (eye drops 0.004%) in the complex therapy of post-primary herpetic keratitis. Material and methods. 106 patients with post-primary herpetic keratitis participated. Patients in group 1 received Panavir® in combination with acyclovir (eye ointment 3%), patients in group 2 — placebo and acyclovir (eye ointment 3%). The study included 6 visits. Results. Complete epithelialization of the cornea at visits 3 and 4 was registered in significantly (p<0.001) more patients from group 1, the average value of the epithelial defect size was also statistically significantly (p<0.001) less in patients of group 1 at visits 3 and 4. In the group 1 registered a statistically significant greater number of patients with non-hyperemic conjunctiva than in the monotherapy group (p<0.001) at visit 4. The severity of corneal syndrome was statistically significantly less in patients from group 1 than in patients from group 2 at visits 3 (p=0.003) and 4 (p<0.001). Conclusion. The conducted clinical study showed the efficacy, safety and good tolerability of Panavir® in combination with acyclovir in the treatment of herpetic keratitis.
Bibliography:
1. Malkhanov VB, Zaynutdinova GKh, Shevchuk NE. The effectiveness of the drug Panavir with anterior uveitis of rheumatic rubric. Annals of Orenburg State University. 2011; 133 (14): 235-8
2. Ministry of Health of the Russian Federation. Her-petic eye diseases [Electronic resource]. 2017. URL: http://www.ookob.ru/sites/default/files/kr_102_gerpeticheskie_ zabolevaniya_glaz.pdf (27 March 2021).
3. Kugusheva АЕ, Slepova OS, Gundorova RA. On the effect of herpes virus infections on the results of corneal graft en-graftment in high-risk keratoplasty. In: Topical issues of ophthalmology. Fedorov Readings. Moscow, 2012; p. 116-7.
4. Maychuk YuF. Optimization of pharmacotherapy of inflammatory diseases of the ocular surface. Russian Ophthalmological Journal. 2008; (3): 18-25.
5. Mironkova ЕА, Demkin VV, Slepova OS, et al. Diagnostics and role of HHV-6 infection in high-risk keratoplasty. Russian Ophthalmological Journal. 2012; (3): 30-4.
6. Chernakova GM, Arzhimatova GSh, Kleshcheva EA, Se-menova ТВ. Herpesviruses in ophthalmology. Vestnik Oftalmologii. 2014; 130 (4): 127-31.
7. Saadouli D, Ammari L, Ben Mansour К, et al. Ocular manifestations of people living with HIV in Tunisia. South Afr J HIV Med. 2021; 22(1): 1193. DOI: 10.4102/sajhivmed.v22i1.1193.
8. Antony F, Pundkar C, Sandey M, et al. IFN-Л Regulates neutrophil biology to suppress inflammation in herpes simplex virus-1 -induced corneal immunopathology. J Immunol. 2021; 206 (8): 1866-77. DOI: 10.4049/jimmunol.2000979.
9. Murchison CE, Petroll WM, Robertson DM. Infectious keratitis after corneal crosslinking: a systematic review. J Cataract Refract Surg. 2021; 47 (8): 1075-80. DOI: 10.1097/j.jcrs. 0000000000000620.
10. Arshad S, Petsoglou C, Lee T, et al. 20 years since the Herpetic Eye Disease Study: Lessons, developments and applications to clinical practice. Clin Exp Optom. 2021; 104 (3): 396-405. DOI: 10.1080/08164622.2021.1877531.
11. O'Neil TR, Hu K, Truong NR, et al. The role of tissue resident memory CD4 T cells in herpes simplex viral and HIV infection. Viruses. 2021; 13 (3): 359. DOI: 10.3390Л/13030359.
12. Wang S, Hou F, Yao YF, Pan D. Efficient establishment of reactivatable latency by an acyclovir-resistant herpes simplex virus 1 thymidine kinase substitution mutant with reduced neuro-nal replication. Virology. 2021; (556): 140-8. DOI: 10.1016/j.virol. 2021.01.016.
13. Pellegrini M, Bernabei F, Barbato F, et al. Incidence, risk factors and complications of ocular graft-versus-host disease following hematopoietic stem cell transplantation. Am J Ophthalmol. 2021; (227): 25-34. DOI: 10.1016/j.ajo.2021.02.022.
| Attachment | Size |
|---|---|
| 2022_04-1_657-661.pdf | 350.78 KB |
Русский
English